文献速递神经免疫

复发型多发性硬化患者脑萎缩与不依赖复发活动的疾病进展的相关性

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项观察性纵向队列研究纳入516例复发型多发性硬化患者(1904次脑MRI扫描),中位随访3.2年。结果显示,不依赖复发活动的疾病进展(PIRA)患者较临床稳定患者脑体积年变化百分比平均差异为-0.36(95%CI -0.60至-0.12;P=0.02),主要由大脑皮层灰质丢失驱动;复发活动患者全脑萎缩亦增加(平均差异-0.18;95%CI -0.34至-0.02;P=0.04)。

要点

  • PIRA患者较临床稳定患者脑体积年变化百分比平均差异为-0.36(95%CI -0.60至-0.12;P=0.02),主要由大脑皮层灰质丢失驱动。
  • 复发活动患者较临床稳定患者全脑萎缩增加(平均差异-0.18;95%CI -0.34至-0.02;P=0.04),大脑皮层和深部灰质均加速丢失。
  • PIRA患者与复发活动患者之间脑萎缩率无差异。

核心结论

  • 复发型多发性硬化患者中,不依赖复发活动的疾病进展(PIRA)与加速的脑萎缩相关,尤其是大脑皮层。
  • 作者认为需要在临床实践中识别PIRA的隐匿表现,并进一步在临床试验中评估针对PIRA患者的治疗策略。

研究设计与样本

  • 观察性纵向队列研究,数据来源于三级大学医院和非大学转诊医院组成的联盟,采集时间为2012年1月至2019年9月。
  • 纳入标准为有规律临床随访且至少有2次适合体积分析的脑磁共振成像(MRI)扫描的复发型多发性硬化患者。
  • 共纳入516例患者(67.4%女性;平均[SD]年龄41.4[11.1]岁;中位[IQR]扩展残疾状态量表评分2.0[1.5-3.0]),共1904次脑MRI扫描;排除质量不足的扫描19次。
  • 中位(IQR)随访时间为3.2年(2.0-4.9),数据分析时间为2020年1月至2021年3月。
  • 根据整个观察期间的临床演变,患者被分为仅复发活动、仅PIRA发作、混合活动和临床稳定四组。

主要发现

  • 放射学炎症活动与多个脑区萎缩率增加相关,年化复发率增加与深部灰质体积加速丢失相关。
  • 与临床稳定患者相比,PIRA患者脑体积丢失率增加(平均差异-0.36;95%CI -0.60至-0.12;P=0.02),主要由大脑皮层灰质丢失驱动。
  • 与临床稳定患者相比,复发活动患者全脑萎缩增加(平均差异-0.18;95%CI -0.34至-0.02;P=0.04),大脑皮层和深部灰质均加速丢失。
  • PIRA患者与复发活动患者之间脑萎缩率无差异。

临床怎么用

  • 作者认为需要在临床实践中识别PIRA的隐匿表现,并进一步在临床试验中评估针对PIRA患者的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The mechanisms driving neurodegeneration and brain atrophy in relapsing multiple sclerosis (RMS) are not completely understood. OBJECTIVE: To determine whether disability progression independent of relapse activity (PIRA) in patients with RMS is associated with accelerated brain tissue loss. DESIGN, SETTING, AND PARTICIPANTS: In this observational, longitudinal cohort study with median (IQR) follow-up of 3.2 years (2.0-4.9), data were acquired from January 2012 to September 2019 in a consortium of tertiary university and nonuniversity referral hospitals. Patients were included if they had regular clinical follow-up and at least 2 brain magnetic resonance imaging (MRI) scans suitable for volumetric analysis. Data were analyzed between January 2020 and March 2021. EXPOSURES: According to the clinical evolution during the entire observation, patients were classified as those presenting (1) relapse activity only, (2) PIRA episodes only, (3) mixed activity, or (4) clinical stability. MAIN OUTCOMES AND MEASURES: Mean difference in annual percentage change (MD-APC) in brain volume/cortical thickness between groups, calculated after propensity score matching. Brain atrophy rates, and their association with the variables of interest, were explored with linear mixed-effect models. RESULTS: Included were 1904 brain MRI scans from 516 patients with RMS (67.4% female; mean [SD] age, 41.4 [11.1] years; median [IQR] Expanded Disability Status Scale score, 2.0 [1.5-3.0]). Scans with insufficient quality were excluded (n = 19). Radiological inflammatory activity was associated with increased atrophy rates in several brain compartments, while an increased annualized relapse rate was linked to accelerated deep gray matter (GM) volume loss. When compared with clinically stable patients, patients with PIRA had an increased rate of brain volume loss (MD-APC, -0.36; 95% CI, -0.60 to -0.12; P = .02), mainly driven by GM loss in the cerebral cortex. Patients who were relapsing presented increased whole brain atrophy (MD-APC, -0.18; 95% CI, -0.34 to -0.02; P = .04) with respect to clinically stable patients, with accelerated GM loss in both cerebral cortex and deep GM. No differences in brain atrophy rates were measured between patients with PIRA and those presenting relapse activity. CONCLUSIONS AND RELEVANCE: Our study shows that patients with RMS and PIRA exhibit accelerated brain atrophy, especially in the cerebral cortex. These results point to the need to recognize the insidious manifestations of PIRA in clinical practice and to further evaluate treatment strategies for patients with PIRA in clinical trials.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cagol A, Schaedelin S, Barakovic M, et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022. PMID: 35575778. doi:10.1001/jamaneurol.2022.1025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。